Pfizer targets another $1.5B in cost cuts by end of 2027
Amid its ongoing efforts to trim $4 billion in spending in 2024, Pfizer in an SEC filing said it is looking to save an additional $1.5 billion over the next several years.
If you are not happy with the results below please do another search
Amid its ongoing efforts to trim $4 billion in spending in 2024, Pfizer in an SEC filing said it is looking to save an additional $1.5 billion over the next several years.
The company announced it would stop the development of its experimental cancer therapy due to liver toxicity experienced by patients in an early-to-mid stage trial.
Many U.S. dairy farms have not yet increased health protections against bird flu for employees during an outbreak in cows, according to workers, activists and farmers, worrying health experts about the risk for more human infections of a virus with pandemic potential.
A group of cancer victims sued Johnson & Johnson on Wednesday, accusing the healthcare company of committing fraud through repeated and continued efforts to use a shell company’s bankruptcy to resolve tens of thousands of lawsuits alleging its talc products contained asbestos and caused cancer.
During the first quarter of the 2024 earnings season, large drugmakers Bayer and Bristol Myers Squibb announced thousands of layoffs in two of the largest workforce reductions so far this year. Coming off years of upheaval in the biotech and pharma sectors, will this be a temporary bump in the road or the beginning of a significant wave of Big Pharma layoffs?
The U.S. Food and Drug Administration’s (FDA) staff on Wednesday pointed to “notable imbalance” in incidence of low blood sugar in patients with type 1 diabetes treated with Danish drugmaker Novo Nordisk’s (NOVOb.CO) long-acting weekly insulin.
Despite weathering a difficult year, biopharma continues to see massive pay gaps between CEOs and their median employees, with top executives often earning hundreds of times more.
The company announced today that it had agreed to buy privately held Human Immunology Biosciences for up to $1.8 billion, bulking up on rare disease medicines as its older multiple sclerosis drugs face tepid demand due to rising competition.
A large fire that broke out at a Novo Nordisk office building in Denmark on Wednesday has been brought under control, the local fire department said.
The experimental drug was in development to treat agitation and restlessness caused by symptoms of Alzheimer’s disease.